ZURICH (Reuters) - Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments helped it to top forecasts in the third quarter. Most of Roche's best-selling cancer drugs do not face imminent generic competition, sparing it the pain from a wave of patent expiries currently sweeping the global drugs industry. ...
Original Source
No comments:
Post a Comment